DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Paul Hudson’s - 1 Ernst & Young - 1 Sanofi - 1 EBIT - 1 Roche - 1 Karen Kwok - 1 Francesco Guerrera - 1 Streisand Neto - 1
Top related locs:
Top related orgs:
Sanofi - 1 Ernst - 1 LSEG - 1 Novartis - 1 Novo Nordisk - 1 GSK - 1 AstraZeneca - 1 X - 1

Search resuls for: "Paul Hudson’s"


2 mentions found


☆ Investors reject Sanofi's cure to sickly valuation
  + stars: | 2023-10-27 | by ( ) www.reuters.com   time to read: +3 min
LONDON, Oct 27 (Reuters Breakingviews) - Sanofi (SASY.PA) investors dislike CEO Paul Hudson’s prescription to reinvigorate the pharmaceutical group’s weak valuation. Analysts polled by LSEG expect the division to hit an EBIT of 1.6 billion euros this year. On listed rival Haleon’s 15.6 times multiple, that business could be worth 25 billion euros. The rest of the Sanofi business may generate EBIT of 11.4 billion euros. The problem is that investors don’t appear to want to take the harsh medicine that leads to a cure.
Persons: Paul Hudson’s, Ernst & Young, Sanofi, EBIT, Roche, Karen Kwok, Francesco Guerrera, Streisand Neto Organizations: Reuters, Sanofi, Ernst, LSEG, Novartis, Novo Nordisk, GSK, AstraZeneca, X, Unilever, Thomson
☆ Sanofi’s ailments are more than skin deep
  + stars: | 2023-02-03 | by ( ) www.reuters.com   time to read: +2 min
LONDON, Feb 3 (Reuters Breakingviews) - Sanofi (SASY.PA) is battling multiple ailments. The $115 billion French pharma group on Friday forecast “low single digit” growth in earnings per share for 2023, disappointing analysts. Hence it’s more reliant on the star asthma and eczema drug Dupixent, which contributed nearly a fifth of Sanofi’s 43 billion euros of sales in 2022. Last August, $36 billion was wiped off Sanofi, GSK (GSK.L) and spinoff Haleon (HLN.L) shares on U.S. litigation fears. It currently trades on 10 times its forecast 2023 earnings, while Novartis (NOVN.S) trades on 13 times.
0 next >>
Total: 2